Our top pick for
Jounce Therapeutics, Inc is a biotechnology business based in the US. Jounce Therapeutics shares (JNCE) are listed on the NASDAQ and all prices are listed in US Dollars. Jounce Therapeutics employs 129 staff and has a market cap (total outstanding shares value) of USD$436.4 million.
|52-week range||USD$2.85 - USD$14.08|
|50-day moving average||USD$10.5651|
|200-day moving average||USD$8.1968|
|Wall St. target price||USD$9.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.628|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Jounce Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Jounce Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Jounce Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Jounce Therapeutics shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Jounce Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$22.6 million.
The EBITDA is a measure of a Jounce Therapeutics's overall financial performance and is widely used to measure a its profitability.
|Gross profit TTM||USD$122 million|
|Return on assets TTM||-36.32%|
|Return on equity TTM||-68.79%|
|Market capitalisation||USD$436.4 million|
TTM: trailing 12 months
There are currently 852,714 Jounce Therapeutics shares held short by investors – that's known as Jounce Therapeutics's "short interest". This figure is 22.8% down from 1.1 million last month.
There are a few different ways that this level of interest in shorting Jounce Therapeutics shares can be evaluated.
Jounce Therapeutics's "short interest ratio" (SIR) is the quantity of Jounce Therapeutics shares currently shorted divided by the average quantity of Jounce Therapeutics shares traded daily (recently around 722638.98305085). Jounce Therapeutics's SIR currently stands at 1.18. In other words for every 100,000 Jounce Therapeutics shares traded daily on the market, roughly 1180 shares are currently held short.
However Jounce Therapeutics's short interest can also be evaluated against the total number of Jounce Therapeutics shares, or, against the total number of tradable Jounce Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Jounce Therapeutics's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Jounce Therapeutics shares in existence, roughly 20 shares are currently held short) or 0.0373% of the tradable shares (for every 100,000 tradable Jounce Therapeutics shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Jounce Therapeutics.
Find out more about how you can short Jounce Therapeutics stock.
We're not expecting Jounce Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Jounce Therapeutics's shares have ranged in value from as little as $2.85 up to $14.08. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Jounce Therapeutics's is 1.2103. This would suggest that Jounce Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase II clinical trial for the treatment of PD-1/PD-L1 inhibitor patients with non-small cell lung cancer and urothelial cancer. It is also developing JTX-4014, a clinical-stage anti-PD-1 antibody for combination therapy; and JTX-1811, a monoclonal antibody designed to selectively deplete T regulatory cells in the tumor microenvironment that is in the IND-enabling phase. The company's product candidate includes JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.